Table 3 Predictors Of Survival
Variable | Univariable | Multivariable | ||
|---|---|---|---|---|
CHR (95%CI) | P-Value | AHR (95%CI) | P-Value | |
Age in years | 1.0 (0.98–1.05) | 0.32 | 1.0 (0.96–1.04) | 0.95 |
Sex: Male | 1.2 (0.64–2.24) | 0.57 | 1.6 (0.76–3.32) | 0.22 |
Study arm: EPOCH | 0.4 (0.10–1.78) | 0.24 | 0.6 (0.13–2.84) | 0.52 |
ECOG | ||||
0–2 | ||||
3–4 | 3.4 (1.10–8.82) | 0.01 | 1.7 (0.55–5.26) | 0.36 |
Not assessed | 2.3 (1.01–5.05) | 0.05 | 1.5 (0.60–3.80) | 0.39 |
BMI | ||||
< 18.5 Kg/m2 | ||||
18.5–24.9 kg/m2 | 0.4 (0.20–0.83) | 0.01 | 0.4 (0.18–0.89) | 0.03 |
> 25 kg/m2 | 0.5 (0.23–1.33) | 0.19 | 0.6 (0.21–2.02) | 0.45 |
Lymphoma stage | ||||
Early stage | ||||
Late stage | 1.8 (0.76–4.04) | 0.19 | 1.6 (0.58–4.60) | 0.35 |
Not assessed | 1.5 (0.49–4.32) | 0.50 | 1 (0.28–3.94) | 0.95 |
Type of lymphoma | ||||
Diffuse large B-cell lymphoma | ||||
Diffuse Large cell lymphoma | 1.2 (0.58–2.63) | 0.58 | 1.0 (0.39–2.43) | 0.95 |
Plasmablastic lymphoma | 2.1 (0.58–7.75) | 0.25 | 1.4 (0.30–6.02) | 0.69 |
NHL Other | 2.5 (0.84–7.28) | 0.10 | 1.7 (0.52–5.74) | 0.37 |
Burkitt’s | 1.0 (0.12–7.45) | 0.96 | 0.3 (0.03–3.45) | 0.33 |
Presence of B-symptoms | 0.9 (0.47–1.63) | 0.67 | 0.9 (0.44–1.96) | 0.85 |
Presence of comorbidity | 0.7 (0.24–1.91) | 0.46 | 0.9 (0.28–2.69) | 0.81 |
Chemotherapy cycles received | ||||
< 6 | ||||
> 6 | 0.2 (0.11–0.43) | < 0.001 | 0.2 (0.10–0.47) | < 0.001 |